Literature DB >> 10029571

Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1.

S Ito1, P Ansari, M Sakatsume, H Dickensheets, N Vazquez, R P Donnelly, A C Larner, D S Finbloom.   

Abstract

Interleukin-10 (IL-10) helps maintain polarized T-helper cells in a T-helper lymphocyte 2 (Th2) phenotype. Part of this process involves the prevention of the development of Th1 cells, which are a primary source of interferon gamma (IFNgamma), a potent activator of monocytes and an inhibitor of Th2 proliferation. Because monocytes and macrophages are important mediators of Th1-type responses, such as delayed-type hypersensitivity, we sought to determine if IL-10 could directly mediate inhibition of IFNgamma- and IFNalpha-induced gene expression in these cells. Highly purified monocytes were incubated with IL-10 for 60 to 90 minutes before the addition of IFNgamma or IFNalpha. IL-10 preincubation resulted in the inhibition of gene expression for several IFN-induced genes, such as IP-10, ISG54, and intercellular adhesion molecule-1. The reduction in gene expression resulted from the ability of IL-10 to suppress IFN-induced assembly of signal transducer and activator of transcription (STAT) factors to specific promoter motifs on IFNalpha- and IFNgamma-inducible genes. This was accomplished by preventing the IFN-induced tyrosine phosphorylation of STAT1, a component of both IFNalpha- and IFNgamma-induced DNA binding complexes. Therefore, IL-10 can directly inhibit STAT-dependent early response gene expression induced by both IFNalpha and IFNgamma in monocytes by suppressing the tyrosine phosphorylation of STAT1. This may occur through the ability of IL-10 to induce expression of the gene, suppressor of cytokine signaling 3 (SOCS3).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029571

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  109 in total

1.  Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling.

Authors:  S P Colgan; R M Hershberg; G T Furuta; R S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS).

Authors:  M E Duddy; G Dickson; S A Hawkins; M A Armstrong
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 3.  Molecular Mechanisms of the Action of Vitamin A in Th17/Treg Axis in Multiple Sclerosis.

Authors:  Mina Abdolahi; Parvaneh Yavari; Niyaz Mohammadzadeh Honarvar; Sama Bitarafan; Maryam Mahmoudi; Ali Akbar Saboor-Yaraghi
Journal:  J Mol Neurosci       Date:  2015-08-30       Impact factor: 3.444

Review 4.  The role of mucosal T lymphocytes in regulating intestinal inflammation.

Authors:  Holm H Uhlig; Fiona Powrie
Journal:  Springer Semin Immunopathol       Date:  2005-06-15

Review 5.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 6.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

Review 7.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

8.  Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses.

Authors:  Claire Gorby; Junel Sotolongo Bellón; Stephan Wilmes; Walid Warda; Elizabeth Pohler; Paul K Fyfe; Adeline Cozzani; Christophe Ferrand; Mark R Walter; Suman Mitra; Jacob Piehler; Ignacio Moraga
Journal:  Sci Signal       Date:  2020-09-15       Impact factor: 8.192

9.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.

Authors:  S Schreiber; P Rosenstiel; J Hampe; S Nikolaus; B Groessner; A Schottelius; T Kühbacher; J Hämling; U R Fölsch; D Seegert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

10.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.